COMPANY

Greenwich LifeSciences

Keywords: oncology cancer Breast Cancer GLSI-100

Location: Stafford, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Dec 16, 2022 Trial start 3: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects source ↗

2031-12 (ESTIMATED) · 3 · Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects · NCT05232916

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05232916	Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects	3	Recruiting	Dec 16, 2022	2031-12 (estimated)